Vertex's HCV Drug VX-950 Gets Fast Track
December 9, 2005
On Thursday, Vertex Pharmaceuticals Inc. announced the Food and Drug Administration has granted its hepatitis C drug "fast track" status, which formalizes agency assistance in drug development and in-process data submissions. FDA grants fast track designation, which can speed up the review process, to therapies that address an unmet need. Vertex's VX-950 therapy, which is in mid-stage human trials, has the potential to shorten the time hepatitis C patients spend on medication, the company said.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.